The global gastric space-occupying devices market was valued at USD 197.5 Million in 2021. As per the report, demand in the market will increase at an impressive 13.7% CAGR over the forecast period, with the market size reaching USD 810.8 Million by 2032. Gastric balloons are leading the market in terms of product with a market share of around 97.0% in 2021.
| Attributes | Key Statistics |
|---|---|
| Gastric Space-Occupying Devices Market Base Year Value (2021) | USD 197.5 million |
| Estimated Market Size (2022) | USD 224.6 million |
| Projected Market Valuation (2032) | USD 810.8 million |
| Value-based CAGR (2022 to 2032) | 13.7% |
| Market Share of Top 5 Countries | 52.0% |
Despite advancements in lifestyle interventions, obesity management pharmacotherapies and metabolic or bariatric surgery, the healthcare burden due to obesity continues to increase. Thus, endoscopic bariatric therapies (EBTs) are gaining traction as they are effective, safe, reversible, and economical. These therapies allow treatment of individuals that are unable to undergo bariatric surgery. Among the endoscopic modalities, the employment of a space-occupying device is one of the most ancient and effective therapies.
Considering the large market size of obesity treatment and the small percentage of patients treated with drugs or bariatric surgery, gastric space-occupying devices can play a major role in the management of obesity.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The market value for gastric space-occupying devices was approximately 5.5% of the overall USD 3.6 Billion worth weight loss management market in 2021. Sales of gastric space-occupying devices increased at a CAGR of 5.4% between 2017 to 2021, owing to high demand for minimally invasive surgeries for obesity management.
The global prevalence of obesity almost tripled between 1975 and 2020. In 2020, globally over 2 billion adults were overweight (body mass index (BMI) > 25) and more than 600 million were obese (BMI > 30). In Europe, nearly 50% of the population is overweight and more than 30% is obese.
Obesity, along with its obesity-related disorders such as diabetes, hypertension, non-alcoholic fatty liver disease, hyperlipidemia, and obstructive sleep apnea has become a global burden. If the incidence of obesity continues on its current trajectory, nearly half of the adult population will have obesity issues by 2030.
Although widely accessible for managing obesity, traditional therapeutic modalities including lifestyle change and dietary counselling are less effective. Contrarily, patients who have not improved after receiving more conventional medical care but prefer not to undergo surgery can consider anti-obesity medical devices.
Gastric space-occupying devices are positioned to bridge the gap between more conservative treatments and more aggressive interventions such as bariatric surgery. Gastric space-occupying device therapy is more advantageous when compared to bariatric surgery, as they are less invasive in nature, and promote ease of performance, and reversibility.
These devices are available upon prescription or as over-the-counter products. Thus, several advantages of these medical devices are expected to increase the demand for gastric space-occupying devices during the forecast period.
Owing to the rising prevalence of obesity and growing demand for minimally invasive surgical procedures in obesity treatment, demand in the global gastric space-occupying devices market is anticipated to grow at a CAGR of 13.7% during the forecast period.
Endoscopic bariatric therapies can be a sustainable treatment option for obesity management. Along with safety and efficacy of data, these therapies will be the most successful treatment in the next few years. Several researchers are focusing on the tandem and progressive use of a combination of space-occupying endoscopic devices and weight loss drug treatment to enhance the stability of weight loss with a long-lasting effect on obesity and associated diseases.
The global healthcare burden due to obesity accounts for around USD 2 trillion yearly or around 2.8% of GDP. This is approximately equal to the worldwide effect of smoking or armed violence, war, and terrorism (McKinsey Global Institute, 2014). The tax on obesity in healthcare systems alone is between 2% and 7% of all healthcare expenditures in developed countries. These figures indicate that obesity is considered one of the top 3 community problems.
To manage the obesity-related healthcare burden, governments are taking initiatives to create awareness among people which will create opportunities for key players to be actively involved in the development and launch of cost-effective solutions for obesity management.
Principal Consultant
The key challenges in the development of gastric space-occupying devices are the lack of specific regulatory guidance and inconsistencies in the time and cost of approval processes in different countries.
Awareness is also an obstacle in the adoption of gastric space-occupying devices. In the realm of weight-loss management, they are still relatively unknown to a large part of the population.
Additionally, increasing product recalls are also hampering growth to an extent. Several gastric space-occupying devices have been withdrawn by manufacturers from the market in the USA after approval by the FDA (e.g., ReShape integrated dual balloon system and Garren gastric bubble.
The use of gastric space-occupying devices is a relatively new technology for weight-loss treatment. Lack of reimbursement for such procedures in most countries can potentially hinder growth. Mostly, health insurance plans have fitness criteria of BMI of 35 or 45 for providing reimbursement for obesity management treatments. Though, patients are eligible for gastric space-occupying devices treatment at BMI 27 and are thus not reimbursed.
Furthermore, most countries treat gastric space-occupying devices as a primary procedure which is in the investigational stage. The therapy is not included in the reimbursement policies of Medicaid (CMC) and Medicare in the USA with a similar scenario existing in Australia, Canada, and other countries in Asia and Europe.
High Incidence of Obesity Related Disorders in USA is Spurring Demand for Gastric Space-Occupying Devices
The USA dominated the North America market in 2021, holding about 83.3% of the market share. As per the report, the trend is expected to continue over the assessment period increasing demand for minimally invasive surgeries for obesity management
In 2017, the American Society for Metabolic and Bariatric Surgery (ASMBS) included gastric space-occupying devices in the list of procedures and devices approved by the society as a treatment option. The sanction and endorsements of this treatment by the ASMBS are expected to increase the adoption of gastric space-occupying devices in the USA.
Rapid Adoption of Anti-Obesity Medica Devices in the UK Will Boost Sales
Demand in the UK market is set to increase at a CAGR of 12.5% in the Europe gastric space-occupying devices market during the forecast period.
Non-invasiveness often favoured by both clinicians and patients in the UK Similarly, innovation and techniques to challenge obesity are increasing in the country, and several key players are competing by innovating.
High adoption of obesity management treatments, and the availability of skilled professionals are some of the key factors contributing to the growth in the market.
Rising Preference for Minimally Invasive Surgeries in China Will Fuel Sales
Sales in the China market are expected to increase at a 14.4% CAGR over the assessment period.
In the past four years, the rates of obesity in China have rapidly increased, along with economic growth, urbanisation, and globalisation. According to the Chinese Residents Chronic Diseases and Nutrition report, in China over 50% of adults and 20% of school-age children were found to be obese in 2020. This figure indicates the need for obesity management and increased demand for EBT, which is ultimately fueling demand for gastric space-occupying devices.
Furthermore, several government initiatives to create awareness are also supplementing the growth in the market. For instane, The Obesity Prevention and Control Society of Chinese Nutrition Society (OPCS-CNS) has collaborated with other government bodies to carry out a series of activities to inspire individuals to pay attention to the obesity problem and take more practical actions.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Demand for Gastric Balloons Will Gain Momentum
Based on product type, sales of gastric balloons held the highest market share of about 97.0% in the market in 2021 and are expected to grow at a CAGR of 13.67% over the forecast period. Through endoscopy, gastric balloons are inserted into the body and offer weight loss of up to 7 to 8 pounds.
An average 7-pound weight loss is possible with the Orbera gastric balloon. The Obalon gastric balloon, on the other hand, offers an average of 7.4 pounds, or 3.42 percent of their total body weight.
Adoption of Obesity Management Pharmacotherapies in Hospitals Will Remain High
Hospitals held the highest share of 59.0% in 2021. Rising prevalence of obesity, along with growing healthcare investments across the globe, and government policies for the execution of superior patient care are driving sales in this segment.
Similarly, new clinical trials conducted in multi-speciality hospitals will provide opportunities to the patients to explore new experimental therapies, thus boosting demand.
The gastric space-occupying devices market is fairly consolidated and led by few market players. These players are focusing on product development and expansion strategies to gain traction in the market. For instance:
| Attribute | Details |
|---|---|
| Estimated Market Size (2022) | US$ 224.6 million |
| Projected Market Valuation (2032) | US$ 810.8 million |
| Value-based CAGR (2022 to 2032) | 13.7% |
| Forecast Period | 2017 to 2021 |
| Historical Data Available for | 2022 to 2032 |
| Market Analysis | US$ million for Value |
| Key Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; and Middle East & Africa |
| Key Countries Covered | The USA, Canada, Brazil, Mexico, Argentina, the UK, Germany, Italy, Russia, Spain, France, BENELUX, India, Thailand, Indonesia, Malaysia, Japan, China, South Korea, Australia, New Zealand, Turkey, GCC, North Africa, and South Africa |
| Key Market Segments Covered | Product, End User, and Region |
| Key Companies Profiled | Apollo Endosurgery, Inc.; Obalon Therapeutics, Inc.; Allurion Technologies, Inc.; Helioscopie; Endalis; MEDSIL; ReShape Medical, Inc.; Lexel Medical; Scientific Intake |
The global gastric space-occupying devices market is worth USD 197.5 Million in 2021 and is set to expand 3.6X over the next ten years.
The gastric space-occupying devices market is expected to reach USD 810.8 Million by the end of 2032, with sales revenue expected to register a 13.7% CAGR.
The rising prevalence of obesity, growing preference for minimally invasive therapies, and the increasing need for gastric space-occupying devices in obesity management are some of the key trends in this market.
USA, UK, Germany, China, and Japan are expected to drive demand for the gastric space-occupying devices industry.
North America is one of the key markets for gastric space-occupying devices, with the USA accounting for about 83.3% of the North American gastric space-occupying devices market in the year 2021.
Demand for gastric space-occupying devices in Europe is expected to register a growth of 12.99% over the next ten years.
The USA, UK, and China are the key producers of gastric space-occupying devices.
Apollo Endosurgery, Inc., Obalon Therapeutics, Inc., Allurion Technologies, Inc., Helioscopie, Endalis, MEDSIL, ReShape Medical, Inc., Lexel Medical, and Scientific Intake, is some of the key players in the gastric space-occupying devices industry.
1. Executive Summary 2. Market Overview 3. Key Market Trends 4. Key Success Factors 5. Market Background 6. Global Market Demand (in Value or Size in USD Million) Analysis 2017 to 2021 and Forecast, 2022 to 2032 7. Global Market Pricing Analysis 8. Global Market Volume (Units) Analysis 2017 to 2021 and Forecast, 2022 to 2032 9. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, by Product 9.1. Gastric Balloons 10. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, by End User 10.1. Hospitals 10.2. Specialty Clinics 10.3. Ambulatory Surgical Centers 11. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, by Region 11.1. North America 11.2. Latin America 11.3. Europe 11.4. East Asia 11.5. South Asia 11.6. Oceania 11.7. Middle East and Africa (MEA) 12. North America Market Analysis 2017 to 2021 and Forecast 2022 to 2032 13. Latin America Market Analysis 2017 to 2021 and Forecast 2022 to 2032 14. Europe Market Analysis 2017 to 2021 and Forecast 2022 to 2032 15. South Asia Market Analysis 2017 to 2021 and Forecast 2022 to 2032 16. East Asia Market Analysis 2017 to 2021 and Forecast 2022 to 2032 17. Oceania Market Analysis 2017 to 2021 and Forecast 2022 to 2032 18. Middle East and Africa (MEA) Market Analysis 2017 to 2021 and Forecast 2022 to 2032 19. Market Structure Analysis 20. Competition Analysis 20.1. Apollo Endosurgery, Inc. 20.2. Obalon Therapeutics, Inc. 20.3. Allurion Technologies, Inc. 20.4. Helioscopie 20.5. Endalis 20.6. MEDSIL 20.7. ReShape Medical, Inc. 20.8. Lexel Medical 20.9. Scientific Intake 21. Assumptions and Acronyms Used 22. Research Methodology
Explore Healthcare Insights
View Reports
Gastric Space-Occupying Devices Market
